Section Arrow
TRDA.NASDAQ
- Entrada Therapeutics
Quotes are at least 15-min delayed:2026/01/05 04:53 EST
Pre Market
Last
 --
-- (--)
Bid
6.72
Ask
16.07
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 10.05
-0.23 (-2.24%)
Day High 
10.36 
Prev. Close
10.28 
1-M High
11.55 
Volume 
217.78K 
Bid
6.72
Ask
16.07
Day Low
9.84 
Open
10.25 
1-M Low
9.4 
Market Cap 
394.42M 
Currency 美元 
P/E 8.66 
%Yield -- 
10-SMA 10.6 
20-SMA 10.65 
50-SMA 9.09 
52-W High 18.75 
52-W Low 4.93 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.57/-4.57
Enterprise Value
446.07M
Balance Sheet
Book Value Per Share
8.91
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
210.78M
Operating Revenue Per Share
2.28
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics0.66-0.92-58.23%0.58PE
Pre Market 0.6845 +0.0245 +3.71%
MREOMereo BioPharma Group plc0.5104+0.0937+22.49%-- 
Pre Market 0.5539 +0.0435 +8.52%
SLSSELLAS Life Sciences Group4.35+0.58+15.38%-- 
Pre Market 4.81 +0.46 +10.57%
ASBPAspire Biopharma Holdings Inc.0.1369+0.005+3.79%-- 
Pre Market 0.1421 +0.0052 +3.80%
RXRXRecursion Pharmaceuticals4.2+0.11+2.69%-- 
Pre Market 4.28 +0.08 +1.90%
Industry overview quotes are at least 15 minutes delayed
Business Description
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.